Improved pharmaceutical compositions with omega-3-containing excipients

Through liquid-liquid separation and grading treatment, high bioavailability ω-3 and EPA fatty acids are extracted from microalgae, solving the problems of dark color and high viscosity of extracts in the prior art, achieving low chlorophyll content and high pole ω-3 excipients with lipid concentrations are suitable for medicine and nutritional products, improving the bioavailability and mass balance of products.

CN118984714APending Publication Date: 2024-11-19NOOTER ERIKSEN INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202280094718.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-11
Filing Date
2022-06-22
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The prior art is difficult to effectively extract high bioavailability omega-3 fatty acids and EPA from microalgae, and the dark color and high viscosity of the extract make it unsuitable as an excipient in medicine and nutritional products, and lacks complete quality. Characterization of equilibrium.

Method used

Oil is extracted from microalgae biomass through the liquid-liquid separation process, and polar lipids and pigments are extracted in fractional fractions using polar and non-polar solvents to separate clean polar lipids, polysaccharides and carotenoids to achieve oil Low chlorophyll content and high polar lipid concentration, reducing opacity and viscosity.

Benefits of technology

Achieve high bioavailability, low viscosity, and low chlorophyll content ω-3 and EPA excipients, ensuring mass balance and complete characterization of oil, suitable for medicine and nutritional products, and improving product bioavailability and sustainability sex.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118984714A_ABST
    Figure CN118984714A_ABST
Patent Text Reader

Abstract

A composition comprising a total lipid concentration wherein at least 20% by weight of the total lipid concentration comprises a polar lipid fraction, greater than about 30% by weight of the polar lipid fraction comprises glycolipids, and wherein the composition comprises a chlorophyll concentration of not greater than 4% by weight thereof, as well as formulations and pharmaceutical compositions comprising the lipid-containing composition.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Related Applications

[0002] This application claims priority to 17 / 718,045, filed on April 11, 2022, which is a continuation-in-part of U.S. application No. 16 / 953,978, filed on November 20, 2020, both of which are incorporated herein by reference.

[0003] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

[0004] not applicable. Background Art

[0005] Nowadays, the pharmaceutical and nutraceutical industries have a high demand for safe, easily available and synergistic excipients, because the performance of pharmaceutical compositions in these industries is considered to need to reach high standards. Excipients include all ingredients that are not considered as "active pharmaceutical ingredients" (API) or other active ingredients in pharmaceutical compositions. Although excipients are traditionally considered to be "inactive" ingredients, it is now considered that excipients are potential determinants of dosage form performance, not only affecting the color, taste and carrier form of, for example, parenteral pharmaceutical compositions, but also affecting factors including but not limited to the stability, bioavailability or patient acceptability of the active ingredients prepared therewith. In addition, it is found that excipients can account for, for example, up to 90% of the drug, and their implementation is monitored by the U.S. Pharmacopeia (USP), and is supervised by international and national organizations such as the Food and Drug Administration (FDA). Therefore, it is very desirable to include a pharmaceutical dosage form of a safe, beneficial excipient, which is easily and cheaply prepared from readily available sources.

[0006] One such excipient component is a fatty acid, such as an omega-3 fatty acid. Omega-3 fatty acids can be used in enteric coatings, i.e., coatings for capsules, tablets, and other oral pharmaceutical compositions. Control of the enteric coating composition can affect the location and rate at which the active ingredient is released in the digestive tract. These compounds can also be found in formulations such as topical creams, suppositories, and soaps.

[0007] Omega-3 fatty acids, also known as long-chain omega-3 oils, are essential for human health, and a lack of them can have serious, negative health effects. These effects range from developmental defects in the brain and neural networks to our cardiovascular health. Even when used as an excipient, studies have shown that omega-3 oils can act as cancer inhibitors. For example, when oleic acid was used with Herceptin for the treatment of breast cancer, it not only acted as a drug delivery vehicle, but actually inhibited breast cancer genes. Other omega-3 acids are thought to have anti-tumor activity and cardiovascular benefits, respectively. Due to supply limitations from aquaculture, fisheries, and other marine sources, the demand for omega-3 oils is currently high, and according to the latest reports, only about 800,000 tons of omega-3 fatty acids can be supplied for human consumption each year. This is far less than the current human nutritional requirement of 1.4 million tons required to supply 500 mg of omega-3 fatty acids per day to the global population, and will be further exacerbated by population growth. Deficiencies in omega-3 fatty acids are observed worldwide, particularly affecting populations located in North America, Central Europe, the Middle East, India, Brazil, and the United Kingdom, with regional and socioeconomic differences between these countries.

[0008] There are three main omega-3 fatty acids in nature. Alpha linoleic acid (ALA), which has 18 carbons and 3 double bonds, is found in, for example, flaxseed, soybean oil, and olives. Docosahexaenoic acid (DHA), which has 22 carbons and 6 double bonds, and eicosapentaenoic acid (EPA), which has 20 carbons and 5 double bonds, are produced only in aquatic species (algae) and can be extracted from krill or fish that eat the algae, or from the algae themselves. Given the thousands of naturally occurring and easily cultured microalgae strains, a specific fatty acid can be selected by selecting the corresponding microalgae strain.

[0009] "Working algae", i.e. algae that grow photosynthetically using sunlight or artificial light sources, contain primarily polar lipids, which belong to the categories of glycolipids and phospholipids. By their nature, these species have a hydrophobic tail and a polar (hydrophilic) head, i.e., they are essentially foreign natural detergents. These substances have particularly high bioavailability and therefore easily enter the human bloodstream to provide the above-mentioned health benefits. Many of these valuable materials have been shown not to occur naturally in other sources, the sustainability of these sources may be questionable, or have proven difficult to obtain in a feasible manner. In addition, their extraction from microalgae efficiently and in their pure, natural, bioavailable form has not been effectively accomplished in a commercially successful manner heretofore, because existing commercial products are hampered by unattractive appearance, odor and texture. Despite their high bioavailability, algal extracts traditionally contain components that give the oils extracted therefrom an overall very dark, nearly black appearance and a highly viscous feel, making them resemble unattractive tarry black solids, with relatively low concentrations of the omega-3 oils themselves.

[0010] Furthermore, the crude products available heretofore could not be fully or adequately analyzed and characterized. In fact, despite decades of research, fully characterized mass balances have not yet been completed or published without reporting the inclusion of high levels (e.g., up to 10% or more) of "unknown" or "unidentified" substances, or by reporting only "pass poor" results and placing these essentially uncharacterized substances in a bucket simply labeled, for example, "carbohydrates." This is particularly unsatisfactory in the case of nutritional and pharmaceutical products.

[0011] In summary, a highly bioavailable, high concentration omega-3, high concentration EPA, high polarity lipid, particularly glycolipid, composition in the form of a low viscosity, low chlorophyll light to dark amber oil for use in nutraceutical and pharmaceutical products, particularly as an excipient in dosage forms of such products, the contents of which have been fully or nearly fully characterized, is currently unavailable, yet highly desirable. Furthermore, a method of obtaining such a highly desirable composition directly from an abundant, highly sustainable algae source would be desirable. Summary of the invention

[0012] The present disclosure describes a solution to the above-mentioned problems, which provides nutritionally and medically helpful, preventive and / or therapeutic dosage forms, which contain low viscosity, low chlorophyll content excipients containing omega-3 and EPA. All dosage forms of the present invention are present in the form of a combination of active ingredients and excipients, and can be produced from specific materials by conventional processing and manufacturing methods known in the art. The dosage form materials using such excipients in the present invention are obtained by extracting oil extracts from microalgae biomass using a liquid-liquid separation process. The crude extract is then fractionated into clean, well-characterized parts, such as polar lipids, polysaccharides and carotenoids, with high efficiency and very high recovery. Due to the innovative fractionation method of the present disclosure, a complete mass balance of oil extracts and entire algal biomass can now be achieved. The desired components are carefully distributed into the excipient formulation so that they can be incorporated into a pharmaceutical composition. Therefore, on the other hand, a pharmaceutical composition rich in omega oil and a method for producing the same are provided.

[0013] In one embodiment, the disclosed method includes a method for producing a low chlorophyll content oil composition, the method comprising the following steps: obtaining algae paste; extracting the algae paste with a polar solvent, such as an alcohol, such as ethanol, to form an algae lipid extract; extracting the resulting extract with, for example, an organic solvent, such as a hydrocarbon, hexane or heptane, to separate the non-polar lipid portion, transferring the alcohol layer, such as the alcohol layer, containing the pigment and polar lipid to the next processing stage; adding water to the alcohol layer, such as the alcohol layer extracted with, for example, heptane, and then continuously extracting with, for example, heptane to extract the pigment portion and separate the polar lipid portion. Polar lipids can be obtained from the polar lipid portion by evaporation, and pigments can also be obtained by evaporating the pigment-containing portion.

[0014] In an alternative embodiment, the disclosed method includes a method of producing a low chlorophyll oil composition, the method including the step of obtaining an algal biomass, the algal biomass including polar and non-polar lipid fractions, and also having a chlorophyll concentration. The method further includes using the polarity characteristics of the polar and non-polar lipid fractions to separate polar and non-polar components in the algal biomass, including substantially separating the chlorophyll concentration and the non-polar lipid fraction. Additional steps include bleaching substantially all of the chlorophyll concentration from the non-polar lipid fraction; and recombining the polar and non-polar lipid fractions to produce a low chlorophyll LC-PUFA oil composition.

[0015] The above-described process embodiments produce attractive compositions for use in both nutraceutical and pharmaceutical applications, particularly with respect to reduced opacity and viscosity.

[0016] In a related embodiment, a method is provided for fractionating and clarifying algal paste into its clean, accurately characterized liquid extracted biomass components, i.e., residual post-extraction biomass ("LEA"), polar lipids, pure neutral lipids, chlorophyll, polysaccharides, carotenoids, with high total recovery and reporting a complete algal biomass balance. The method comprises the following steps: obtaining algal paste; extracting the algal paste with a polar solvent, e.g., an alcohol, such as ethanol, to form an alcohol extract, e.g., of algal lipids; extracting the resulting alcohol extract, e.g., with an organic solvent, e.g., a hydrocarbon, hexane or heptane, to separate a non-polar lipid fraction, transferring the alcohol layer, e.g., containing pigments and polar lipids, to the next processing stage; adding water to the alcohol layer, e.g., extracted with heptane, e.g., followed by continuous extraction with, e.g., heptane, to extract the pigment fraction and separate out the polar lipid fraction.

[0017] The present disclosure also relates to bioavailable compositions rich in LC-PUFA, ω-3, EPA, polar lipids and glycolipids / phospholipids, which are particularly suitable for nutraceutical compositions and pharmaceutical compositions, which can be considered as health or pharmaceutical compositions, and are considered to have other valuable end products. The starting material of such compositions can be derived from the algae described herein. In one embodiment, a composition is disclosed, the composition comprising a polar lipid fraction in a total lipid concentration of at least 20% by weight of the total lipids; wherein the polar lipid fraction comprises at least 40% by weight of glycolipids; and wherein the composition comprises a chlorophyll concentration of no greater than 4% by weight thereof.

[0018] The composition prepared as described above, having a polar lipid fraction of at least 20 wt.% of the total lipids and a glycolipid fraction of at least 40 wt.% of the polar lipids, but having a chlorophyll fraction of less than 4 wt.%, as described more fully below, may further include a formulation with added non-polar lipids and / or nutritional oils such as DHA or other beneficial additives, which also helps provide certain beneficial combinations of more bioavailable, nutritionally rich, lighter colored, and lower viscosity oils.

[0019] These and other features of the present disclosure are discussed in further detail in the following detailed description. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 A schematic diagram of the extraction process steps of an exemplary method for preparing oil according to embodiments of the present disclosure is disclosed.

[0021] Figure 2 is based on Figure 1 Photographic depictions of embodiments of compositions of the present disclosure prepared by the described exemplary methods, having desired target concentrations of LC-PUFAs, polar lipids, ω-3, EPA, and glycolipids enriched with reduced chlorophyll, as well as desired bioavailability, color, and viscosity of the oil composition, embodiments of which are disclosed herein.

[0022] Figure 3 is a photographic depiction of a powder obtained by one embodiment of the disclosed methods, the powder consisting essentially of non-lipid components including polysaccharides contained in a crude ethanolic algal extract, such as prepared according to embodiments of the methods described herein.

[0023] Figure 4 is a graphical depiction of the spectral characterization of one embodiment of an ethanol extract of Nannochloropsis and products after pigment removal as described in Example 1. Y-axis = AU (Absorption Units), X-axis = nm (nanometers, wavelength).

[0024] Figure 5 is a graphical depiction of a UV-Visible spectroscopy characterization of one embodiment of an algal extract as described in Example 2. Y-axis = AU (light absorption units), X-axis = nm (nanometers, wavelength). DETAILED DESCRIPTION

[0025] The following detailed description illustrates the claimed disclosure by way of example and not limitation. This specification will clearly enable those skilled in the art to make and use the claimed disclosure, and describes several embodiments, modifications, variations, alternatives and uses of the claimed disclosure. In addition, it should be understood that the claimed disclosure is not limited to the details and components specifically set forth in the following description or illustrated by way of the accompanying drawings in its application. The claimed disclosure can have other embodiments and can be practiced or carried out in various ways. In addition, it should be understood that the (wording and terminology) used herein are for descriptive purposes and should not be considered restrictive.

[0026] As used herein, the term "polar lipid" refers to an amphipathic lipid having a hydrophilic head and a hydrophobic tail. Examples of polar lipids include phospholipids and glycolipids.

[0027] As used herein, the term "non-polar lipid" refers to a fat molecule in which the charge distribution is very uniform, and the molecule does not have positively and negatively charged ends. Examples of non-polar lipids include triglycerides of various fatty acids in oils (e.g., triglycerides of EPA, triglycerides of palmitoleic acid, etc., including mixtures thereof, such as triglycerides (TAGs) containing variants or combinations of these fatty acids.

[0028] As used herein, the abbreviations "EPA" and "DHA" refer to eicosapentaenoic acid and docosahexaenoic acid, respectively, as well as salts and ethyl ester forms of each compound. In its naturally occurring acid form, EPA is an unsaturated chain of 20 carbons terminating in a carboxylic acid functional group. However, those of ordinary skill in the art understand that natural variants of this acid form include basic salts (in which the deprotonated carboxylic acid is stabilized by a counter anion) and ethyl esters (in which two or more carbons are covalently bonded to sp 3-hybridized oxygen, thereby forming an ester). In the case of the ethyl ester form, EPA has 22 carbons. Similarly, the acidic form of DHA is an unsaturated chain of 22 carbons culminating in a carboxylic acid functional group, and is believed to have natural variants including basic salts and ethyl ester forms. Thus, DHA in the form of the ethyl ester has 24 carbons. The basic salt forms of eicosapentaenoic acid and docosahexaenoic acid may occur spontaneously due to the specific chemical environment in which they are found. Conversion to the ethyl ester variants is equally easy, and these variants are also used as drugs to treat, for example, high blood triglyceride levels. Any use of the acronyms "EPA" and "DHA in this application should not be construed to exclude basic salts or ethyl ester variants of either compound unless they are expressly excluded.

[0029] As used herein, the term "pharmaceutical composition" refers to a composition that is taken by a patient for therapeutic, curative or preventive purposes, which contains active ingredients and inactive ingredients. Pharmaceutical compositions whose active ingredients are primarily used to promote nutrition are referred to as "nutraceuticals." Pharmaceutical compositions whose active ingredients are primarily pharmacological drug products are referred to as "drugs."

[0030] As used herein, the term "dosage form" refers to the form of a pharmaceutical composition in which its components are administered. The dosage form includes active ingredients and inactive ingredients. The dosage form can be liquid, solid or gaseous, and can include, but is not limited to, tablets, pills, capsules, wafers, lozenges, liquid solutions, etc. The dosage form can be "swallowable", which means that the dosage form is used parenterally, and can also be "chewable", in which the ingestion of the dosage form is substantially assisted by chewing. The dosage form can also be "soluble", in which the preferred route of ingestion of the dosage form is to first dissolve in an aqueous medium such as water.

[0031] As used herein, the terms "inactive" and "excipient" refer to any and all compounds and elements that are not active ingredients of the composition. The definitions herein follow the definitions described in the Code of Federal Regulations (CFR) adopted by the Food and Drug Administration (FDA). It is specified that excipients must meet strict requirements for purity and toxicity. Excipients should not be interpreted as necessarily having no therapeutic benefit. Excipients, such as excipients formed by the ω-3 oil composition of the present invention, can have synergistic and / or separate therapeutic effects due to being included in the dosage form. The use of one or more excipients belonging to a specific recognized class (e.g., fillers, softeners, dyes, coating agents) does not exclude the use of another recognized class of excipients in the same embodiment of the present invention.

[0032] As used herein, the term "active ingredient" therefore also refers to the definition adopted by the FDA and the definition described in the CFR. By providing a descriptive and non-limiting summary of the term, an active ingredient refers to any substance intended to directly provide a cure, relief, treatment, or any other pharmaceutical or nutraceutical effect.

[0033] As used herein, the term "antioxidant" refers to any substance that stops, inhibits or interferes with the chemical process of oxidation and its deleterious effects. Antioxidants include a wide range of compounds whose properties and general uses are known to those of ordinary skill in the art.

[0034] As used herein, the term "vitamin" refers to any organic molecule or a group of chemically related molecules that are considered by those of ordinary skill in the art to be essential micronutrients required for the normal metabolic function of mammalian organisms. These nutrients are generally not synthesized in sufficient quantities in the organism and must therefore be obtained through diet. For the purposes of the claimed invention, most major health organizations consider the following list to include vitamins known to be essential for human health: vitamin A, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B7, vitamin B9, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, and choline in some cases. Please note that the foregoing list is intended to illustrate rather than limit. Please note that specific vitamin names refer to "vitamers" or groups of related compounds, managed under a single name. For example, the term "vitamin A" refers to an equivalent vitamin comprising trans-retinol and trans-retinyl esters. In this article, the vitamin terms listed above include all known compounds in the related equivalent vitamins.

[0035] As used herein, the term "mineral" refers to essential nutrients other than oxygen, carbon, hydrogen and nitrogen that are also chemical elements. The major mineral nutrients are considered to be calcium, phosphorus, potassium, sodium and magnesium, but may further include elements present in trace amounts in the human diet, including sulfur, iron, chlorine, cobalt, copper, zinc, manganese, molybdenum, iodine and selenium.

[0036] To produce the disclosed embodiments of the composition of clarified algal biomass, algal paste can be obtained using standard procedures known to those of ordinary skill in the art, which appears as a dark green or even black, high viscosity oil. See, for example, the production of the algal paste and useful varieties of algae employable as described in U.S. Pat. No. 8,591,912 B1 (hereinafter referred to as "Kadam and Goodall"), which is incorporated herein by reference and discussed elsewhere herein.

[0037] As part of the liquid-liquid extraction, the process for obtaining an algal biomass extract, as well as the raw algae and extraction process for preparing the algal biomass, may include the following steps:

[0038] Algae biomass, such as algae paste, is obtained or prepared by suitable algae species suitable for producing such target algae biomass. Typically, microalgae can be harvested by conventional means (including but not limited to filtration, flotation and centrifugation), and algae paste is produced by concentrating the harvested microalgae to the desired solid weight %. In certain embodiments, the microalgae used in the inventive method is a member of one of the following phyla: Chlorophyta, Cyanobacteria (cyanobacteria) and Heterokontophyta. In certain embodiments, the microalgae used in the inventive method is a member of one of the following classes: Bacillariophyceae, Eustigmatophyceae and Chrysophyceae. In certain embodiments, the microalgae used in the methods of the invention are members of one of the following genera: Nannochloropsis, Chiarella, Dunaliella, Scenedesmus, Selenastrum, Oscillatoria, Phormidium, Spirulina, Amphora, Trachydiscus, and Ochromonas. Non-limiting examples of species of microalgae that can be used in the methods of the present invention include: Achnanthes orientalis, Agmenellum spp., Amphiprorahyaline, Amphora coffeiformis, Amphoracoffeiformis var. linea, Amphora coffeiformis var. punctata, Amphora coffeiformis var. taylori, Amphora coffeiformis var. tenuis, Amphoradelicatissima, Amphora delicatissima var. capitata, Amphora sp., Anabaena, Ankistrodesmus, Ankistrodesmus falcatus), Boekelovia hooglandii, Borodinella sp.), Botryococcus braunii, Botryococcus sudeticus, Bracteococcus minor, Bracteococcus medionucleatus, Carteria, Chaetoceros gracilis, Chaetoceros muelleri, Chaetoceros muelleri var. subsalsum, Chaetoceros sp., Chlamydomas perigranulata, Chlorella anitrata, Chlorella antarctica, Chlorella aureoviridis, Chlorella candida, Chlorella capsulate, Chlorella desiccate), Chlorella ellipsoidea, Chlorella emersonii, Chlorella fusca, Chlorella fusca var. vacuolata, Chlorella glucotropha, Chlorella infusionum, Chlorella infusionum var. actophila, Chlorella infusionum var. auxenophila, Chlorella kessleri, Chlorella lobophora, Chlorella luteoviridis, Chlorella luteoviridis var. aureoviridis, Chlorella luteoviridis var.lutescens), Chlorella miniata, Chlorella minutissima, Chlorella mutabilis, Chlorella nocturna, Chlorella ovalis, Chlorella parva, Chlorella photophila, Chlorella pringsheimii, Chlorella protothecoides, Chlorella protothecoides var. acidicola, Chlorella regularis, Chlorella regularis var. minima, Chlorella regularis var. umbricata, Chlorella reisiglii, Chlorella saccharophila, Chlorella ellipsoidea saccharophila var.ellipsoidea), Chlorellasalina, Chlorella simplex, Chlorella sorokiniana, Chlorella sp., Chlorella sphaerica, Chlorellastigmatophora, Chlorella vanniellii, Chlorellavulgaris, Chlorella vulgaris fo.tertia, Chlorella vulgaris var.autotrophica, Chlorella vulgarisvar.viridis, Chlorella vulgaris var.vulgaris, Chlorella vulgaris var.vulgaris fo.tertia), Chlorella vulgaris var. vulgaris fo. viridis, Chlorella xanthella, Chlorella zofingiensis, Chlorella trebouxioides, Chlorella vulgaris, Chlorococcum infusionum, Chlorococcum sp., Chlorogonium, Chroomonas sp., Chrysosphaera sp., Cricosphaera sp., Crypthecodinium cohnii, Cryptomonas sp., Cyclotella cryptica, Cyclotella meneghiniana, Cyclotella sp.), Dunaliella sp., Dunaliella bardawil, Dunaliella bioculata, Dunaliella granulate, Dunaliella maritime, Dunaliella minuta, Dunaliella parva, Dunaliella peircei, Dunaliella primolecta, Dunaliella salina, Dunaliella terricola, Dunaliella tertiolecta, Dunaliella viridis, Dunaliella terricola, Eremosphaera viridis, Eremosphaera sp., Effipsoidon sp., Euglena spp.), Franceia sp., Fragilaria crotonensis, Fragilaria sp., Gleocapsa sp., Gloeothamnion sp.), Haematococcus pluvialis, Hymenomonas sp., Isochrysis aff.galbana, Isochrysis galbana, Lepocinclis, Micractinium, Microstar, Monoraphidium minutum, Monoraphidium sp., Nannochloris sp., Nannochloropsis salina, Nannochloropsis sp., Navicula acceptata, Navicula biskanterae, Navicula pseudotenelloides, Navicula pelliculosa, Navicula saprophila), Navicula sp., Nephrochloris sp., Nephroselmis sp., Nitschia communis, Nitzschia alexandrina, Nitzschia closterium, Nitzschia communis, Nitzschia dissipata, Nitzschia frustulum, Nitzschia hantzschiana, Nitzschia inconspicua, Nitzschia intermedia, Nitzschia microcephala, Nitzschia pusilla, Nitzschia pusilla elliptica, Nitzschia pusilla monoensis, Nitzschia quadrangular), Nitzschia sp., Ochromonas sp.), Oocystis parva, Oocystis pusilla, Oocystis sp., Oscillatoria limnetica, Oscillatoria sp., Oscillatoria subbrevis, Parachlorella kessleri, Pascheria acidophila, Pavlova sp., Phaeodactylum tricomutum, Phagus, Platymonas sp., Pleurochrysis carterae, Pleurochrysis dentate, Pleurochrysis sp., Prototheca wickerhamii, Prototheca stagnora), Prototheca portoricensis, Prototheca moriformis, Prototheca zopfii, Pseudochlorella aquatica, Pyramimonas sp., Pyrobotrys, Rhodococcus opacus, Sarcinoid chrysophyte, Scenedesmus armatus, Schizochytrium, Spirogyra, Spirulina platensis, Stichococcus sp., Synechococcus sp., Synechocystis f, Tagetes erecta, Tagetes patula), Tetraedron, Tetraselmis sp., Tetraselmissuecica, Thalassiosira weissflogii, Trachydiscus, and Viridiella fridericiana.

[0039] Preferred algae species are those that are, for example, rich in LC-PUFA oil sources. Examples of such algae strains are strains from the Nannochloropsis or Chlorella algae species.

[0040] The algal paste or other suitable forms of algal biomass can be processed as follows: extraction, for example, with a polar solvent such as an alcohol, including ethanol, to form an alcoholic extract of algal lipids with a low water content (forming an ethanolic extract of Nannochloropsis lipids (hereinafter referred to as "EEN"); extraction of the obtained EEN with, for example, an organic solvent such as a hydrocarbon hexane or heptane to separate the non-polar lipid fraction (e.g., triglycerides, waxes, carotene), thereby forming a "non-polar lipid fraction" in the heptane layer ( Figure 1 F#1). The alcohol layer containing pigments and polar lipids can be transferred to further stages of processing. Figure 1 Other polar solvents may be considered, such as carbon dioxide or carbon dioxide-ethanol mixtures.

[0041] The next stage of processing may include adding water to the polar solvent layer extracted, for example, with heptane, followed by a continuous extraction with, for example, heptane to extract the pigment fraction (see Figure 1 , heptane layer, F#3) and separate the polar lipid fraction (see Figure 1 , water-alcohol layer, F#2). Polar lipids can be obtained from the F#2 fraction by evaporation, and pigments can be obtained by evaporating the F#3 fraction. The F#1 layer may contain a certain amount of chlorophyll and carotenoids, which can be removed by methods known to those skilled in the art (e.g., known methods for producing edible oils). Examples of these methods include adsorption-filtration using silica gel, bleaching clays such as B80, T41, activated carbon, etc. As a result of the selective removal of chlorophyll from the F#1 fraction, in this embodiment, a largely transparent to dark amber, including slightly reddish, somewhat liquid to semi-solid oil can be obtained.

[0042] In an alternative embodiment, a method for producing an oil composition with a low chlorophyll content, the algal biomass or algal paste thus obtained includes polar lipids and non-polar lipid fractions, and also has a chlorophyll concentration. The polarity characteristics of the polar lipid and non-polar lipid fractions of the biomass are used to separate the polar components and non-polar components in the algal biomass, including substantially separating the chlorophyll concentration and non-polar lipid fractions. As shown in Example 2 below, additional steps include bleaching substantially all of the chlorophyll concentration from the non-polar fraction; and recombining the polar and non-polar lipid fractions to produce an oil composition with a low chlorophyll content.

[0043] In addition to the low chlorophyll content aspect of the composition, the present invention also provides an isolated oil derived from algae, which is rich in LC-PUFA, including at least one omega-3 fatty acid, such as but not limited to EPA or DHA, at least in part in the form of whole and unhydrolyzed phospholipids and whole and unhydrolyzed glycolipids extracted by the above method. The oil produced by this method is unexpectedly rich in polar lipids, such as phospholipids and glycolipids. Krill oil is known to have a higher bioavailability in mammals than fish oil, which contains almost only neutral lipids (triglycerides), due to its phospholipids (a polar lipid). See Jan Philipp Schuchardt et al., Lipids in Health and Disease 2011, 10: 145. Notably, oil extracted from algae such as Nannochloropsis sp. using the methods of the present invention exhibits a bioavailability to mammals that even exceeds that of krill oil.

[0044] After separation of algae oil, algae oil can be incorporated into pharmaceutical preparations. The active ingredient of pharmaceutical preparations can include but is not limited to medicines, vitamins or dietary supplements, other oils or antioxidants containing ω-3. As non-limiting examples, the incorporation of separated algae oil can include the mode of direct mixing with active ingredient, which is by incorporating other excipients known to provide optimal dosage form, and by using algae oil or algae oil mixture and other excipient material coating formulations The component and surface. In a preferred embodiment, the incorporation of separated algae oil can be by applying algae oil to the outside of gel capsules, pills, tablets or other edible dosage forms, to increase the lipophilicity of the dosage form. The following examples are explanations of the present invention, both for clarifying and determining the specific components of oil compositions, and for producing oils rich in LC-PUFA and low chlorophyll, low polysaccharide content, as further described herein:

[0045] Example

[0046] Embodiment 1:

[0047] 2.1 Process scheme of this embodiment (see Figure 1 )

[0048] 1) Weigh out 100 g of Nannochloropsis algae paste (22-27% solids in water). (Stage 1, Figure 1 )

[0049] 2) Place the algae paste in a 2L flask and add 850ml of ethanol. (Stage 1, Figure 1 )

[0050] 3) Extract the algae by vigorous stirring at 70°C for 45 minutes. (Stage 1, Figure 1 )

[0051] 4) Filter the solid algae residue from the ethanol extract (vacuum filtration). (Stage 2, Figure 1 )

[0052] 5) Place the ethanol extract from the previous stage in a separatory funnel (2 L), add 300 mL of heptane to the resulting extract, stir vigorously for 2 min, and separate the layers. Carefully select the upper layer and place it in a separate flask to obtain about 120 mL of a green heptane layer. (Stage 3 Figure 1 )

[0053] 6) Add another 100 mL of heptane to the ethanol layer and stir vigorously for 2 min. The layers will separate (ethanol layer - lower layer, heptane layer - upper layer). Carefully select the upper layer and combine it with the heptane layer obtained in the previous stage (obtain ~200-220 mL of combined green heptane layer, F#1 fraction). (Stage 4, Figure 1 )

[0054] 7) Add 1 gram of silica gel to the entire heptane layer obtained, stir vigorously for 5 minutes, and then filter the slurry through a layer of 1 gram of silica gel (activated carbon or T41 bleaching clay can be used instead of silica gel). Due to the different properties of various silica gels, activated carbons and bleaching clays, the actual amount of the materials should be adjusted according to the factory conditions. (Stage 8, Figure 1 )

[0055] 8) Remove the lower (ethanol) layer from stage 6 of the protocol, add 350 mL of water and 200 mL of heptane, and shake the mixture vigorously for 2 min. After about 5 min of settling phase separation, carefully select the upper layer and place it in a separate flask (about 400 mL of green heptane layer is obtained at this stage). (Stage 5, Figure 1 )

[0056] 9) Extract the lower layer from the above stage several times with 200 mL of heptane ((3x200 mL)). Carefully select the upper layer and combine it with the heptane layer obtained in the previous stage. ((Obtain approximately 1000-1020 mL of combined green heptane layer, F#3 fraction)). (Stage 5, Figure 1 )

[0057] 10) The extracted lower layer contains the clear polar lipids (F#2). This fraction can be purified by 3 g of Amaze-N bleaching adsorbent, such as from Helix Chromatography (15 E. Palantine Rd. #118, Prospect Heights, IL 60070; helixchrom.com) (or similar adsorbents can be used if desired).

[0058] 11) The obtained fraction was evaporated in vacuum with heating at <45°C.

[0059] The above process steps and experimental results demonstrate an efficient exemplary method for liquid-liquid extraction to remove chlorophyll and a portion of carotenoids from phototrophic (autotrophic) algal extracts (e.g., Nannochloropsis or Chlorella lipids). By using the above embodiments of the disclosed methods, more than 99% of the chlorophylls alpha and beta and pheophytin, as well as approximately two-thirds of the carotenoids (medium polarity carotenoids) were removed from the ethanol extract (EEN) of Nannochloropsis. In doing so, at least 90% by weight, preferably greater than 95% by weight, more preferably greater than 97.5% by weight, even more preferably greater than 98.0% by weight, and most preferably greater than 99% by weight of the original mass balance was fully retained and its major components could be characterized without the need to simply retain a large portion of the mass balance as uncharacterized or characterized only "by subtraction" or "by difference". See Table 1: Extract mass balance (composition) and Table 2: Major components of the ethanol extract of Nannochloropsis for mass and weight % analysis of the components. (99.86% by weight of the total algal biomass.) See Figure 4 Spectral characteristics of the ethanol extract of Nannochloropsis salsa after pigment removal.

[0060] Table 1. Extraction mass balance (composition)

[0061]

[0062]

[0063] Table 2. Major components of the ethanol extract of Nannochloropsis

[0064]

[0065] While viscosity measurements may vary to some extent, depending on factors such as temperature, compositional concentrations of the various ingredients in the formulation, etc., viscosity readings for embodiments of Nannochloropsis extracts prepared as described herein were recorded as @ 165,000 mPa.'s after mixing the polar lipid fraction with the neutral lipid fraction at 25°C as described herein.

[0066] In summary, the product shown in Example 1 can be decomposed into three main fractions of the influent ethanol extract of Nannochloropsis algae (EEN): 1) fraction (F#1), non-polar lipids, mainly triglycerides; 2) fraction (F#2), polar lipids, including glycolipids and phospholipids; and fraction (F#3), a medium polar fraction, containing di- and monoglycerides, free fatty acids (FFA), carotenoids and chlorophyll. The clarified F#1 and F#2 fractions can be used as a source of valuable lipids rich in palmitoleic acid and eicosapentaenoic acid (EPA). F#3 is a concentrate of natural pigments, including chlorophyll, astaxanthin, zeaxanthin, etc., and also has value as a food additive. Fractions F#1-3 can each be used as a food additive and are valuable raw materials with high biological potential.

[0067] Example 2

[0068] A dark green paste sample of algal biomass was prepared generally according to the method outlined in U.S. Patent No. 8,591,912B1 (see generally column 6, line 62 to column 9, line 3) and discussed herein (see, e.g., at

[0025] ). The algal biomass paste was extracted with hot anhydrous ethanol. Specifically, 66 g of algal paste, 3 x 250 mL of ethanol were each stirred at 75° C. at 500 rpm for 30 minutes, and centrifuged at 4450 rpm for 10 minutes to obtain a sample algal extract.

[0069] Analysis of the oil extracts showed that the major polar lipids in the algae samples were: 1) glycolipids (monogalactosyl diacylglycerol (MGDG) and digalactosyl diacylglycerol (DGDG) and 2) phospholipids (phosphatidlycholine, phosphatidylethanolamine and phosphatidylinositol) (see Table 3 herein).

[0070]

[0071] Table 3

[0072] *) - permanent weight after drying at room temperature (final moisture content not tested)

[0073] **)-TAG, DAG, FFA, phytosterol

[0074] ***)-Glycolipids (AMGDG, MGDG, DGDG, SQDG)

[0075] ****)-Phospholipids (PC, PE, PI, PA, PG)

[0076] Embodiments of the bioavailable, low chlorophyll content, polar lipid-rich, LC-PUFA-rich, omega-3 oil-rich oils disclosed herein as quantified herein are prepared from the above starting materials using the following additional steps:

[0077] 1) Separation of polar lipids from a mixture of nonpolar lipids, chlorophyll, and other components based on differences in polarity.

[0078] 2) bleaching chlorophyll from the remaining non-polar lipid components using a well-developed protocol for vegetable oil bleaching, generally as described in Example 1 above; and, for example, adding 1 gram of silica gel to the entire heptane layer obtained, and after vigorous stirring for 5 minutes, filtering the slurry through a 1 gram silica gel layer (activated carbon or T41 bleaching clay can be used instead of silica gel). Due to the different properties of various silica gels, activated carbons and bleaching clays, the actual amount of the materials used should generally be adjusted according to factory conditions.

[0079] 3) The polar lipid fraction (1) is combined with the bleached non-polar lipid (2).

[0080] A bioavailable polar lipid-rich, low-chlorophyll oil composition is obtained, which is generally low in viscosity and has an almost transparent to light brown color. Spectral analysis see Figure 5 The composition is a waxy solid at an ambient temperature @ 70 degrees Fahrenheit. The composition melts when heated and exhibits low viscosity when mixed with other oils such as triglycerides, etc.

[0081] Analysis of oil compositions of embodiments of the bioavailable oils of the present disclosure prepared using the above methods described herein indicated that oils having the following components and characteristics (column 1) and component ranges (column 2) listed in Table 4 were obtained from the algal biomass:

[0082]

[0083]

[0084] Table 4

[0085] As known to those skilled in the art, the weight % of the components of the oil disclosed in the present application and the appropriate changes of other characteristics can be obtained by changing the process adopted. However, preferably, the weight % of the polar lipid part of the total lipid concentration of the oil produced exceeds 20%, preferably exceeds 30%, more preferably exceeds 40%, even more preferably exceeds 50%, and is also more preferably about 70% or higher. In addition, preferably, the weight % of chlorophyll concentration in the oil product is less than 4% of the total oil product weight, more preferably, it is less than 3.0%, more preferably, it is less than 2.0%, even more preferably, it is less than 1.0%, 0.75%, 0.50%, 0.2%, even more preferably, it is less than 0.1% or lower. In addition, preferably, the weight % of polysaccharide concentration in the oil product is about 4% of the total oil product weight or less, more preferably, it is less than 3.0%, more preferably, it is less than 2.5%, 2.0%, even more preferably, it is less than 1.0%, 0.5% or less. In addition, the weight % of glycolipids based on the weight % of total polar lipids exceeds 20%, preferably exceeds 30%, more preferably exceeds about 40%, even more preferably exceeds 50%, 60%, 70%, and more preferably 80% or more, and glycolipids account for the weight % of total oil composition exceeds 10%, more preferably 20%, and more preferably about 25% or more. In addition, the weight % of phospholipids based on the weight % of polar lipids exceeds 20%, more preferably exceeds 30%, and more preferably exceeds 35%, and phospholipids account for the weight % of total oil composition exceeds 20%, more preferably 30%, and more preferably 40%. Although not bound by any particular theory, applicants believe that by these combinations including very low chlorophyll concentration characteristics in the oil product, attractive, light-colored, close to transparent to amber, always to darker amber colors are produced, and in a preferred embodiment, close to transparent to amber. In addition, the EPA concentration of the total oil product content produced is at least 20 weight %, more preferably at least 25 weight %, and more preferably at least about 30 weight % or higher. Similarly, the omega-3 content of the oil product is at least 20% by weight, more preferably at least 25% by weight, and even more preferably at least 30, 40% by weight or more. Considered as a whole, the LC-PUFA content of the oil product is at least 20% by weight, at least 25%, 30%, 40% and 50% by weight.

[0086] Improvements in the bioavailability of the oil produced thereby are also achieved. Furthermore, unlike some prior art methods of extracting and fractionating microalgae, the disclosed methods do not involve aggressive chemistry (such as the use of, for example, strong inorganic acids that often destroy polar lipids and can significantly degrade other valuable portions of the algal biomass).

[0087] In embodiments of the methods of the present disclosure, a powder of non-lipid components (eg, polysaccharides of the crude ethanol algal extract) is also obtained. See Table 3.

[0088] It should also be noted that for the high polar content oils containing LC-PUFA, ω-3, EPA of the present disclosure, the weight % of the following chlorophylls is greatly reduced: 1) chlorophyll a, 2) prochlorophyll a, and 3) methylchlorophyll. Preferably, the weight % of chlorophyll in the composition is less than 4% of the total weight % of the composition, preferably less than 3%, more preferably less than 2%, even more preferably less than 1%, even more preferably less than 0.5%, 0.5%, and even more preferably less than 0.1%.

[0089] In another embodiment of the composition of the present disclosure, the composition is enhanced with several other ingredients by weight, including carotenoids, such as carotene (alpha and beta), zeaxanthin (yellow pigment), canthaxanthin and zeaxanthin (red pigment), and the total carotenoids account for more than 0.5%, preferably more than 1% of the total weight of the extract.

[0090] In other alternative embodiments of the present disclosure, bioavailable, high polar lipid-containing, EPA-containing, low chlorophyll content oil compositions (embodiments of which are disclosed herein) can be present as formulations to which other useful ingredients have been added. These other useful ingredients can be added alone or in the form of one or more combinations (e.g., in combination with other essential oils, dietary supplements, health supplements, etc.). Specific examples include, but are not limited to—1) other ω3-containing oils or components, such as DHA and EPA (e.g., in the form of neutral lipids extracted as products in the present invention or from external sources), lysophospholipids from the present invention, or ethyl esters of DHA or EPA from external sources; 2) antioxidants, such as carotenoids, including astaxanthin, lutein, zeaxanthin, lycopene, carotene (α and β), cryptoxanthin, and mixtures thereof (including the carotenoid portion of the present invention); 3) vitamins, such as vitamins C and D; 4) cannabinoids, such as cannabidiol (CBD), and 5) other combinations. It should be understood that such preparations including some of these materials with less color and / or lower viscosity composition distribution can reduce the overall color distribution and viscosity of the preparation including the fatty acid composition with high polar lipid, high glycolipid and low chlorophyll concentration prepared by the embodiments of the disclosed methods herein. Therefore, this can be achieved by, for example, including non-polar lipids, which are added back from the original biomass feedstock, or added back from an external source, or by preparing a preparation showing such attributes.

[0091] Examples of nutraceutical formulations including a mixture of the polar EPA portion described above with DHA (ω-3) may advantageously be in a ratio of 10-90 to 90-10, with preferred levels of the mixed polar EPA formulation component being 20-50%. Uses of such formulations include their own use as a key food supplement / nutraceutical for cardiovascular health, mood, anti-depression, etc., and use as a delivery system for other neutral lipids and components formulated therewith. The formulation may be DHA, other neutral forms of EPA, or a mixture thereof. Astaxanthin at a level of 0.04% to 10%, preferably 0.1% to 2%, more preferably 0.2% to 1%, may also be beneficially formulated with pure polar EPA lipids or a mixture thereof with neutral EPA and / or EPA. Another component that may be beneficially added to such a formulation is coenzyme Q10 at a level of about 1-50%, preferably about 2-20%, of polar EPA, which component may be pure or in any of the above formulations.

[0092] Formulation mixtures with added neutral lipids, for example, can be used to achieve various viscosity levels, such as 50,000 cps, preferably less than 10,000 cps, more preferably less than about 2,000 cps, and most preferably about 300 cps or less, among other attributes.

[0093] In view of the above, it will be seen that the objects and advantages of the present disclosure have been achieved and other advantageous results have been attained.

[0094] As various changes could be made in the above constructions without departing from the scope of the present disclosure, it is intended that all matter contained in the above description or shown in the accompanying drawings shall be interpreted as illustrative and not in a limiting sense.

Claims

1. A composition comprising a total lipid concentration, wherein at least 20% by weight of the total lipid concentration comprises a polar lipid fraction, greater than about 30% by weight of the polar lipid fraction comprises glycolipids, and wherein the composition comprises a chlorophyll concentration of no greater than 4% of its weight percent.

2. The composition of claim 1, wherein the total lipid concentration of the composition is at least about 75% by weight of the composition as a whole.

3. The composition of claim 1, wherein the total lipid concentration of the composition is at least about 90% by weight of the composition as a whole.

4. The composition of claim 1, wherein at least about 50% by weight of the total lipid concentration comprises the polar lipid fraction.

5. The composition of claim 1, wherein the composition comprises a chlorophyll concentration of no greater than about 1.0% of its total weight %.

6. The composition of claim 1, wherein the composition further comprises at least about 20% by weight total ω3.

7. The composition of claim 6, wherein the weight percent of total ω3 of the composition is at least about 30 weight percent.

8. The composition of claim 1, wherein the composition further comprises at least about 20% by weight total EPA.

9. The composition of claim 1, wherein the glycolipid comprises at least about 60% by weight of the polar lipids of the composition.

10. The composition of claim 1, wherein the composition comprises at least about 20% by weight glycolipid.

11. The composition of claim 1, wherein the composition comprises at least about 40% by weight glycolipid.

12. The composition of claim 1, wherein the composition further comprises a phospholipid, wherein the phospholipid comprises at least about 40% by weight of the polar lipids of the composition, based on the weight percent of the polar lipids of the composition.

13. The composition of claim 12, wherein the phospholipids comprise at least about 60% by weight of the polar lipids of the composition.

14. The composition of claim 1, wherein the composition comprises at least about 20% by weight phospholipids.

15. The composition of claim 14, wherein the composition comprises at least about 40% by weight phospholipids.

16. The composition of claim 1, wherein the composition comprises no more than about 4% by weight polysaccharide.

17. The composition of claim 16, wherein the composition comprises no more than about 2% by weight polysaccharide.

18. The composition of claim 1, wherein the composition has a clear to dark amber color under ambient light.

19. The composition of claim 1, wherein the composition is characterized by having a viscous to waxy oil texture at 70 degrees Fahrenheit.

20. A composition comprising a total lipid concentration, wherein at least 50 weight % of the total lipid concentration comprises a polar lipid fraction; wherein the polar lipid fraction comprises glycolipids of at least 40 weight % of the polar lipid fraction of the composition, and wherein the composition comprises a chlorophyll concentration of no greater than 1% of its weight %.

21. The composition of claim 20, wherein the total composition comprises at least about 20% by weight glycolipid.

22. The composition of claim 21, wherein the total composition comprises at least about 40% by weight glycolipid.

23. The composition of claim 20, wherein the total lipid concentration of the composition is at least about 75% by weight of the composition as a whole.

24. The composition of claim 23, wherein the total lipid concentration of the composition is at least about 90% by weight of the composition as a whole.

25. The composition of claim 20, wherein at least about 70% by weight of the total lipid concentration comprises the polar lipid fraction.

26. The composition of claim 20, wherein the composition further comprises at least about 20% by weight total ω3.

27. The composition of claim 26, wherein the weight % of total ω3 of the composition is at least about 30%.

28. The composition of claim 20, wherein the composition further comprises at least about 20% by weight total EPA.

29. The composition of claim 20, wherein the composition further comprises at least about 40% by weight of the polar lipids of the composition of phospholipids.

30. The composition of claim 29, wherein the phospholipids comprise at least about 60% by weight of the polar lipids of the composition.

31. The composition of claim 20, wherein the composition comprises at least about 20% by weight phospholipids.

32. The composition of claim 31, wherein the composition comprises at least about 40% by weight phospholipids.

33. The composition of claim 20, wherein the composition comprises no more than about 4% by weight polysaccharide.

34. The composition of claim 33, wherein the composition comprises no more than about 1% by weight polysaccharide.

35. The composition of claim 20, wherein the composition has a viscous to waxy oil texture at 70 degrees Fahrenheit.

36. A preparation comprising: A composition comprising a total lipid concentration, wherein at least 20% by weight of the total lipid concentration comprises a polar lipid fraction, greater than about 30% by weight of the polar lipid fraction comprises glycolipids, and wherein the composition comprises a chlorophyll concentration of no greater than 4% of its weight percent; and, One or more additives selected from the group consisting of: Others contain omega 3 oils, antioxidants, vitamins and minerals.

37. The formulation of claim 36, wherein the antioxidant is selected from the group consisting of astaxanthin, lutein, zeaxanthin, lycopene, alpha carotene, beta carotene, ubiquinone, and cryptoxanthin.

38. The formulation of claim 37, wherein the astaxanthin is present in 0.04% to 10% of the formulation.

39. The formulation of claim 37, wherein the ubiquinone is present at 1-50% of the formulation, preferably 2-20% of the formulation.

40. The formulation of claim 36, wherein the one or more additives is DHA.

41. The formulation of claim 36, wherein the one or more additives is ALA.

42. The formulation of claim 36, wherein the formulation composition comprises a chlorophyll concentration of no greater than 0.1% by weight thereof.

43. The formulation of claim 36, wherein the vitamin is selected from the group consisting of vitamin A, beta carotene, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B7, vitamin B9, vitamin B12, vitamin C, vitamin D2, vitamin D3, vitamin E, vitamin K, and choline.

44. The formulation of claim 36, wherein the mineral is selected from the group consisting of calcium, phosphorus, potassium, sodium, magnesium, sulfur, iron, chloride, cobalt, copper, zinc, manganese, molybdenum, iodine, and selenium.

45. A pharmaceutical composition comprising: A composition comprising a total lipid concentration, wherein at least 20% by weight of the total lipid concentration comprises a polar lipid fraction, greater than about 30% by weight of the polar lipid fraction comprises glycolipids, and wherein the composition comprises a chlorophyll concentration of no greater than 4% of its weight percent; and, One or more additives selected from the group consisting of: Others contain omega 3 oils, antioxidants, vitamins and minerals.

46. ​​The pharmaceutical composition of claim 45, wherein the composition is in a form that can be swallowed.

47. The pharmaceutical composition of claim 45, wherein the composition is in chewable form.

48. The pharmaceutical composition of claim 45, wherein the composition is in a soluble form.

49. The pharmaceutical composition of claim 45, wherein the total lipid concentration is present on the outer surface of the pharmaceutical composition.